The global eosinophilia therapeutics market is poised for substantial growth, with a projected market value of USD 413 million in 2023. By the end of the forecast period in 2033, the market is expected to accumulate a value of USD 739.62 million, reflecting a robust compound annual growth rate (CAGR) of 6%. This growth can be attributed to the increasing global prevalence of eosinophilia and the availability of diverse treatments to manage the condition.
Eosinophilia therapeutics is focused on treating eosinophilic disorders, a group of diseases marked by an abnormal increase in eosinophils—white blood cells that play a role in the body’s immune response. These disorders can impact various bodily systems, including the skin, respiratory system, and gastrointestinal tract. As awareness of eosinophilic disorders rises and medical research continues to advance, there is a growing demand for targeted and personalized therapies to manage symptoms effectively.
Between 2018 and 2022, the eosinophilia therapeutics market registered a CAGR of 3.3%, signaling a steady demand for treatment options during the historical period. With the surge in the incidence of eosinophilic diseases, both new and existing treatments are gaining traction, propelling the market towards further growth.
The increasing focus on developing more specialized and effective therapies tailored to individual needs is expected to drive continued market expansion. As a result, the global eosinophilia therapeutics market is positioned for a strong upward trajectory, offering promising opportunities for both current and emerging players in the healthcare sector.
Key Takeaways from the Market Study:
- The Eosinophilia therapeutics market is expected to grow at a value of 6% CAGR in the forecast period 2023-2033.
- By distribution channel, hospital pharmacies are expected to procure 45% market share for eosinophilia therapeutics market.
- North America is expected to procure 43% market share for eosinophilia therapeutics market.
- Europe is expected to possess 38% market share for eosinophilia therapeutics market.
“Increase in research and development activities along with growing awareness regarding the ailment is spurring the growth of Eosinophilia therapeutics market.” states an FMI analyst
Expanding Market Need: Access Our Full Report for In-Depth Analysis and Trends!
Competitive Landscape:
Key players in the eosinophilia therapeutics market are GlaxoSmithKline plc, Sanofi, Takeda Pharmaceutical Company Limited, Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Merck & Co., Inc, Eli Lilly and Company, AstraZeneca, Bayer AG, Gilead Sciences, Inc, Regeneron Pharmaceuticals, Inc., Cipla Inc.
- In 2021, Takeda announced the results of a Phase 3 clinical trial for its drug reslizumab for the treatment of eosinophilic asthma. The results showed that the drug improved lung function and reduced the number of severe asthma attacks in patients with the condition.
- Roche, another key player in the eosinophilia therapeutics market has also been working on the development of a new therapy for the treatment of EGIDs. The therapy, called risankizumab, is a biologic drug that specifically targets the cytokine IL-23, which is involved in the development of eosinophilic inflammation. The drug is currently in late-stage clinical development.
Key Segments Profiled in the Eosinophilia Therapeutics Market Industry Survey:
Drug Class:
- Corticosteroids
- Immunosuppressant
- Monoclonal Antibody
Type:
- Blood Eosinophilia
- Tissue Eosinophilia
Route of Administration:
- Oral
- Intravenous
Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa(MEA)
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube